In contrast, mice treated with darolutamide in combination with radium-223 prevented the PSA increase throughout the study, as the relative mean PSA change at sacrifice was 102% of the pre-treatment level, indicating inhibitory tumor control by the combination treatment (Figure 2B). This evidence concerns the gene KLK3 and neoplasm.